Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Calzone, Frank J ^a   Cajulis, Elaina ^a   Chung, Young Ah ^a   Tsai, Mei Mei ^a   Mitchell, Petia ^a   Lu, John ^a   Chen, Ching ^a   Sun, Jilin ^a   Radinsky, Robert ^a   Kendall, Richard ^a   Beltran, Pedro J ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANITUMAB; INSULIN RECEPTOR; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1H7; MONOCLONAL ANTIBODY 391; MONOCLONAL ANTIBODY ALPHA IR3; MONOCLONAL ANTIBODY F1 A; MONOCLONAL ANTIBODY F1 B; MONOCLONAL ANTIBODY F1 C; MONOCLONAL ANTIBODY L2 A; MONOCLONAL ANTIBODY L2 B; MONOCLONAL ANTIBODY L2 C; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; EPITOPE MAPPING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIGAND BINDING; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SUBCUTANEOUS TISSUE TUMOR; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING SITES; CELL PROLIFERATION; EPITOPE MAPPING; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MCF-7 CELLS; MICE; MICE, NUDE; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84873277950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055135     Document Type: Article

References (32)

1. Adams TE, Epa VC, Garrett TP, Ward CW, (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093.
2. De Meyts P, Whittaker J, (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1: 769-783.
3. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, et al. (1999) Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19: 7203-7215.
4. Baserga R (1998) The IGF-1 receptor in normal and abnormal growth. In: Dickson RB, Salomon DS, editors. Hormones and growth factors in development and neoplasia. New York: Wiley-Liss. 269-287.
5. Dupont J, LeRoith D, (2001) Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res 55Suppl 2: 22-26.
6. Siddle K, (2011) Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47: R1-10.
7. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R, (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623.
8. Gallagher EJ, LeRoith D, (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21: 610-618.
9. Gualberto A, Pollak M, (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-3021.
10. Pollak M, (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169.
11. Yee D, (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 104: 975-981.
12. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, et al. (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics.
13. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, et al. (1983) Monoclonal antibodies to receptors for insulin and somatomedin-C. Journal of Biological Chemistry 258: 6561-6566.
14. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, et al. (1992) A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. Journal of Biological Chemistry 267: 12955-12963.
15. Steele-Perkins G, Roth RA, (1990) Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun 171: 1244-1251.
16. Gallagher EJ, LeRoith D, (2011) Minireview: IGF, Insulin, and Cancer. Endocrinology 152: 2546-2551.
17. Kaneda A, Feinberg AP, (2005) Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 65: 11236-11240.
18. De Meyts P, (2008) The insulin receptor: a prototype for dimeric, allosteric membrane receptors? Trends Biochem Sci 33: 376-384.
19. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, et al. (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5: 1935-1944.
20. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, et al. (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27: 5800-5807.
21. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang Y, et al. (2012) Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined With Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients With Advanced Solid Tumors. Clin Cancer Res.
22. Mazot P, Cazes A, Dingli F, Degoutin J, Irinopoulou T, et al. (2012) Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment. PLoS One 7: e33581.
23. Belleudi F, Marra E, Mazzetta F, Fattore L, Giovagnoli MR, et al. (2012) Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle 11: 1455-1467.
24. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073.
25. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, et al. (2011) Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 337: 644-654.
26. Martins AS, Ordonez JL, Amaral AT, Prins F, Floris G, et al. (2011) IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis. PLoS One 6: e19846.
27. Ackerman ME, Pawlowski D, Wittrup KD, (2008) Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 7: 2233-2240.
28. Beltran PJ, Mitchell P, Hwang D, Cajulis E, Chung Y-A, et al. (2007) Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody. Presented at the 19th International EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007; San Francisco, CA, American Association for Cancer Research Meeting. A67.
29. Hewish M, Chau I, Cunningham D, Hewish M, Chau I, et al. (2009) Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Patents on Anti-Cancer Drug Discovery 4: 54-72.
30. Xiong L, Kasuya J, Li SL, Kato J, Fujita-Yamaguchi Y, (1992) Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor. Proc Natl Acad Sci U S A 89: 5356-5360.
31. Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, et al. (2009) Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem 284: 10254-10267.
32. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, et al. (2002) Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Molecular Cancer Therapeutics 1: 1349-1353.